Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
...
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associ...
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
- Associated Therapies
- -
Screening to Prophylax Against Clostridium Difficile Infection -
- Conditions
- Interventions
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- William Beaumont Hospitals
- Target Recruit Count
- 1294
- Registration Number
- NCT02996487
- Locations
- 🇺🇸
William Beaumont Hospital, Troy, Michigan, United States
Drug Delivery Devices for Osteomyelitis
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2018-11-27
- Target Recruit Count
- 51
- Registration Number
- NCT02968693
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Yulin Orthopedics Hospital of Chinese and Western Medicine, Yulin, Guangxi, China
Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 399
- Registration Number
- NCT02945241
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- NuBiyota
- Target Recruit Count
- 19
- Registration Number
- NCT02865616
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile
- Conditions
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Per Hellström
- Target Recruit Count
- 60
- Registration Number
- NCT02857582
- Locations
- 🇸🇪
Gävle Hospital, Gävle, Gävleborg, Sweden
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 199
- Registration Number
- NCT02814916
- Locations
- 🇱🇹
Klaipeda Children's Hospital /ID# 235652, Klaipeda, Lithuania
🇧🇬University Multiprofile Hospital for Active Treatment Deva Maria EOOD Burgas /ID# 235965, Bulgas, Bulgaria
🇧🇬MHAT (Multiprofile Hospital for Active Treatment) /ID# 235539, Kozloduy, Bulgaria
Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Memorial University of Newfoundland
- Registration Number
- NCT02801656
- Locations
- 🇨🇦
Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada
Neonatal Vancomycin Trial
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- PENTA Foundation
- Target Recruit Count
- 242
- Registration Number
- NCT02790996
- Locations
- 🇬🇷
Aghia Sophia Children's Hospital (A), Athens, Greece
🇮🇹Policlinico San Matteo, Pavia, Italy
🇪🇸Hospital Sant Joan de Deu, Barcelona, Spain
Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
- Conditions
- Interventions
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT02787057
Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections
- Conditions
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 450
- Registration Number
- NCT02774382
- Locations
- 🇩🇰
Køge sygehus, Køge, Denmark
🇩🇰Hvidovre Hospital, Hvidovre, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.